Citi's research team picked Insilico Medicine as its top stock in Chinese AI-driven drug discovery, setting an HK$85 target and projecting the global market to reach about US$500 billion by 2030. The bank also initiated coverage on XtalPi Holdings with an HK$8 target while flagging its limited pipeline depth.
Citi designated Insilico Medicine as its preferred stock in AI-driven drug discovery with an HK$85 target price, calling the sector the industry's next major trend.
The bank's research team said Chinese AI-driven drug discovery (AIDD) is accelerating as AI's speed and cost advantages draw investor attention. Citi projects the global AI drug discovery market will reach about US$500 billion by 2030, up from roughly 6 percent penetration of the US$313 billion global pharmaceutical R&D investment expected in 2026.
Citi maintained its Buy rating on Insilico with an HK$85 target, describing the company as a hybrid platform-and-pipeline business whose proprietary AIDD platform can generate "superior and differentiated" clinical assets with exponential value-creation potential. The bank also initiated coverage on XtalPi Holdings with an HK$8 target, citing the company's combination of physical AI, robotic experiments, and intelligent orchestration, while flagging limited pipeline depth and unvalidated commercialization output.
Insilico shares closed at HKD 47.00 on Aug. 28, up 4.54 percent, implying roughly 81 percent upside to Citi's target. The stock has traded between HKD 29.98 and HKD 80.90 over the past year. Insilico reported about US$106 million in first-half 2026 revenue, up 287 percent year over year, achieving its first profitable half-year since listing with adjusted net profit exceeding US$51 million.
The endorsement arrives as AI drug discovery gains broader industry traction. Owkin signed a licensing deal with Boehringer Ingelheim in September for access to its AI research platform, following AstraZeneca's May license of the same technology and Sanofi's five-year partnership expansion in June, according to Reuters. Insilico's partners include Eli Lilly, Servier, Takeda, SK Biopharmaceuticals, and Qilu Pharmaceutical.
Insilico is set to join the HKEX Tech 100 Index on Sept. 14, a move expected to enhance trading liquidity and attract inflows from index-tracking passive funds and Mainland Chinese investors via Southbound Stock Connect. The company has previously been included in the MSCI Global Small Cap, Hang Seng Healthcare, Hang Seng Biotechnology, and FTSE Global index series.
The Citi endorsement provides institutional confirmation for a sector where AIDD penetration remains low but the addressable market is large. Investors will watch whether the HKEX Tech 100 inclusion on Sept. 14 triggers passive fund inflows into Insilico, and whether XtalPi can demonstrate commercialization progress to justify its new coverage.
This article is for informational purposes only and does not constitute investment advice.
